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a b s t r a c t
Pelvic recurrence after resection of rectal adenocarcinoma is a feared complication and is 
associated with a worse prognosis and low resectability rates. The differential diagnosis 
is diffi cult, as biopsy is seldom performed preoperatively. We report two cases of desmoid 
pelvic tumor after resection of rectal adenocarcinoma. Therapeutic options and literature 
review are described.
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Tumor desmóide
Adenocarcinoma de reto
Recidiva pélvica
r e s u m o
Achado incomum após ressecção de adenocarcinoma do reto: relato 
de dois casos
O aparecimento de tumor pélvico após ressecção de adenocarcinoma de reto é complicação 
temida e está associado à pior prognóstico e baixos índices de ressecabilidade. O diagnós-
tico diferencial é difícil, pois o diagnóstico histológico usualmente não é realizado no pré-
-operatório. São relatados dois casos em que houve o aparecimento de tumor pélvico após 
a ressecção de adenocarcinoma de reto, com diagnóstico histológico de tumor desmóide. 
As condutas adotadas e revisão da literatura são descritas.
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Introduction
The postoperative follow-up of rectal adenocarcinoma aims 
at the identification of metastasis and local recurrence. The 
latter has been reported between 3% and 35%,1 is difficult to 
be confirmed histologically in the preoperative period and 
has low rates of resectability. We report two cases in which 
pelvic recurrence of adenocarcinoma was suspected, but 
which were actually desmoid tumors (DTs). 
Case reports
Case 1
NBS, female, 74 years old, submitted to abdominoperineal 
resection for rectal adenocarcinoma. The patient had pelvic 
infection and perineal suture dehiscence in the immediate 
postoperative period, showing good resolution with medical 
therapy. Four months after the surgery, she reported pelvic 
pain without alterations in the physical examination. She un-
derwent a computed tomography (CT) screening of the abdo-
men and pelvis, which identified a heterogeneous lesion with 
hypodense center, irregular and poorly defined borders, mea-
suring 5 cm in diameter, located in the pelvic region.
Positron-emission computed tomography (PET-CT) was 
performed, which showed areas of increased uptake in the 
presacral region, measuring 6.0 × 4.0 cm, with sacrococcygeal 
bone invasion, suggestive of neoplastic recurrence (Fig. 1). The 
carcinoembryonic antigen (CEA) was normal (0.2 ng / dL). It 
was then assumed that it was a recurrence of the primary le-
sion. Surgical resection was proposed and, at surgery, a new 
CT scan showed no evidence of distant metastases, disclosing 
the presence of the same lesion in the sacral region, with a 
slight increase in size (Fig. 2). Posterior approach was used for 
the surgical procedure and the lesion was resected together 
with the sacral vertebrae S4 and S5, with free macroscopic 
margins. Primary closure of the wound was performed. The 
patient recovered uneventfully and was discharged on the 
seventh postoperative day. Histopathological examination 
showed the tumor was a DT, involving soft tissue and adjacent 
bone tissue, measuring 9.0 × 7.0 × 4.0 cm, with free margins. 
The patient is being followed on an outpatient basis and has 
no evidence of recurrence after six months postoperatively. 
Case 2
MFB, 63 years old, female, was submitted to rectosigmoidec-
tomy with coloanal anastomosis for rectal adenocarcinoma. 
She developed pelvic suppuration and underwent another 
lowering surgical procedure after 12 months. Five months 
after the second surgery, the patient had pelvic pain and a 
presacral pelvic lesion was diagnosed by CT. PET-CT was per-
formed, which showed areas of increased uptake in the presa-
cral region, measuring 6.0 cm. CEA levels were also normal (3 
ng/dL). As the patient refused surgical treatment, a CT-guided 
percutaneous biopsy was performed with histological diagno-
sis of DT. Treatment with tamoxifen was started and after two 
months there was partial regression of the lesion and disap-
pearance of symptoms.
Discussion
This report describes two cases of rectal adenocarcinoma 
that evolved with pelvic tumors, of which histological analy-
sis showed they were desmoid tumors.
DT, also known as deep fibromatosis, is a non-encapsulat-
ed tumor that originates from the fibroblasts of musculoapo-
neurotic tissues. It was first described in 1832, later receiving 
the name of desmoid to identify its macroscopic appearance 
(from the Greek word desmos, meaning tendon or ligament).2,3,4 
DTs account for to 0.03% of all cancers and 3% of all soft tissue 
tumors. The estimated incidence in the general population is 
2-4 new cases per million per year.4,5,6 Its peak incidence is 
between 25 and 35 years old, with a female predominance of 
2:1.5,6,7,8 
Its etiology is not well known, but, in general, it is related 
to mutations in the activation of beta-catenin (for sporadic 
tumors) and APC gene mutations.9,10 These tumors are locally 
Fig. 2 – CT - axial view - presacral tumor lesion.
Fig. 1 – CT - sagittal view – tumor lesion aspect.
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aggressive, with no potential for the development of metasta-
ses, eventually causing deformity of the adjacent organs, pain 
and organic dysfunction, depending on the affected area.2,10,12 
DTs may be solitary or multiple and can occur anywhere, 
including the trunk, extremities and abdomen. Currently, it 
is known that these tumors may be sporadic or related to Fa-
milial Adenomatous Polyposis (FAP) and are more commonly 
found in the abdominal cavity of these patients.3,5,7,13 Another 
group described is represented by young women and the in-
fluence of estrogen is important in these cases.9,14 This evi-
dence is confirmed by the higher incidence of DT in women 
during their reproductive life, due to apparent tendency of 
tumors developing during pregnancy or shortly after, by its 
occasional disappearance after menopause, the experimental 
production of similar lesions in animals treated with estrogen 
administration and the benefit of antiestrogen therapy in pa-
tients with this type of tumor.5,11 
Its natural history and clinical behavior is unpredictable, 
ranging from fast-growing forms to indolent tumors and may 
remain stable.5,13 Spontaneous regression of this neoplasm 
is rare and has been reported in approximately 5% of cases.9 
Imaging techniques, including ultrasound, CT and magnetic 
resonance imaging (MRI) are used for the diagnosis and eval-
uation of these lesions.5,15,16 The CT is important to assess 
intra-abdominal lesions; MRI is preferable to assess extremi-
ties, head and neck, chest and abdominal wall.9 PET-CT has 
become increasingly important to predict prognosis of these 
lesions and assess their aggressiveness, as well as to aid in 
determining the best treatment for these patients.17 A biopsy 
is usually required to confirm the diagnosis.2,9 
Some aspects are common in both cases, such as the pres-
ence of pelvic infection postoperatively, relatively early onset 
of lesions (before the sixth month postoperatively) and low 
values  of CEA. In most cases in which the presence of a pelvic 
tumor after surgery is observed, histological investigation is 
not performed or resection is not possible, and thus, it may be 
supposed that the occurrence of postoperative DT is higher. 
Considering that surgical resection in cases of pelvic le-
sions is difficult and DT has a high recurrence rate,7,11 albeit 
responsive to pharmacological treatment, histological diagno-
sis becomes essential to establish the differential diagnosis, 
as the conduct and prognosis may change completely. Among 
the drugs used are non-steroidal anti-inflammatory drugs 
(NSAIDs), antihormonal therapy and chemotherapy.11,13,18,19 
Drug therapy aims to induce remission, decrease the size 
of lesions, their morbidity and recurrence rates. In general, 
NSAIDs (Sulindac and Indomethacin) and estrogen recep-
tor modulators (usually tamoxifen) are considered first-line 
drugs to treat DTs. The tumor does not need to have a posi-
tive estrogen receptor to respond to tamoxifen. Aromatase in-
hibitors also appear to have important effect on the disease, 
but further studies are needed to verify that, as there are cur-
rently no randomized studies to prove their efficacy. Approxi-
mately half of the DTs show complete or partial response to 
drug therapy; however, it is difficult to prove whether this is 
due to treatment or biological behavior of the lesion. Drug 
therapy can also be used together with surgical treatment as 
an adjuvant therapy.3 
The use of chemotherapy has also shown to be contro-
versial. Recently validated, this treatment modality may be 
considered when there are specific indications, usually after 
failure of the non-cytotoxic treatment in patients with unre-
sectable tumors, patients considered unfit for surgery or those 
with residual disease.13 Moreover, chemotherapy may be used 
as neoadjuvant therapy to reduce tumor size preoperatively, 
or as palliative treatment. The more effective and less toxic 
chemotherapy regimen is the combination of methotrexate 
and vinblastine or doxorubicin and dacarbazine.3   
The use of radiation therapy in the treatment of DT is also 
controversial. It is not known if there are benefits to using 
radiotherapy after surgical treatment of lesions with compro-
mised margins, aiming at preventing relapses. However, ra-
diation therapy has been used in patients with unresectable 
disease or, eventually, as adjuvant therapy after incomplete 
tumor resection. The recommended dose is 50-60 Gy in 5-7 
weeks, with 1.8-2 Gy per fraction.4 However, it may be con-
traindicated in patients previously submitted to neoadjuvant 
therapy.
In DTs, the definition of optimal treatment is controversial 
and, considering their rarity, there are few consistent publica-
tions in the literature, most with a small number of cases, 
making it difficult to establish definitive behaviors. The sim-
ple observation seems to be a reasonable option for asymp-
tomatic and mildly symptomatic patients, who should be fol-
lowed through imaging methods. Tumors that remain stable 
or decrease in size generally do not require any treatment.3,11 
Local resection, which has been recommended for a long 
time for the treatment of DT, has been the treatment of choice 
for most authors. This resection should be wide and include the 
margins, as these tumors usually show non-palpable extensions 
to adjacent organs, hindering the intraoperative assessment of 
disease extension.4,6,8,9,13,18,19 The safety margin should be 1 cm.15 
Although some authors have reported that the involvement 
of the surgical margin does not change the rate of local recur-
rence,20 others have clearly shown that the surgical margin sta-
tus is the most significant single factor in determining the rate 
of local recurrence in patients treated surgically,9 which may be 
decisive in the evolution of pelvic lesions.
Because this is a rare tumor, its diagnosis is still difficult 
and little hypothesized. Thus, the possibility of developing a 
desmoid tumor in the pelvis must then be considered. 
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